Cumberland Pharmaceuticals (NASDAQ:CPIX) Stock Price Passes Above 200 Day Moving Average – Should You Sell?

Shares of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $3.28 and traded as high as $4.92. Cumberland Pharmaceuticals shares last traded at $4.65, with a volume of 208,690 shares trading hands.

Analyst Upgrades and Downgrades

A number of research firms have commented on CPIX. Weiss Ratings restated a “sell (d-)” rating on shares of Cumberland Pharmaceuticals in a research note on Monday, December 29th. Wall Street Zen upgraded shares of Cumberland Pharmaceuticals to a “hold” rating in a research report on Saturday, January 10th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has a consensus rating of “Sell”.

Cumberland Pharmaceuticals Stock Performance

The firm has a market capitalization of $70.61 million, a PE ratio of -19.67 and a beta of -0.53. The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.11 and a current ratio of 1.23. The business’s fifty day simple moving average is $3.35 and its 200-day simple moving average is $3.29.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last released its earnings results on Tuesday, November 4th. The specialty pharmaceutical company reported ($0.06) EPS for the quarter. The company had revenue of $8.29 million during the quarter. Cumberland Pharmaceuticals had a positive return on equity of 5.13% and a negative net margin of 8.06%.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Two Sigma Investments LP lifted its position in shares of Cumberland Pharmaceuticals by 16.5% in the third quarter. Two Sigma Investments LP now owns 37,591 shares of the specialty pharmaceutical company’s stock worth $117,000 after buying an additional 5,326 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in Cumberland Pharmaceuticals by 11.1% in the 3rd quarter. Dimensional Fund Advisors LP now owns 280,869 shares of the specialty pharmaceutical company’s stock worth $876,000 after acquiring an additional 27,980 shares during the last quarter. Bridgeway Capital Management LLC increased its stake in Cumberland Pharmaceuticals by 2.3% in the 2nd quarter. Bridgeway Capital Management LLC now owns 188,355 shares of the specialty pharmaceutical company’s stock worth $631,000 after acquiring an additional 4,200 shares during the last quarter. XTX Topco Ltd purchased a new stake in shares of Cumberland Pharmaceuticals during the 2nd quarter worth approximately $34,000. Finally, Heron Bay Capital Management bought a new position in shares of Cumberland Pharmaceuticals during the 2nd quarter valued at approximately $111,000. Hedge funds and other institutional investors own 15.51% of the company’s stock.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development, manufacture and commercialization of hospital and acute care products. Founded in 1993, the company has built a portfolio of branded therapeutics designed to address critical care needs in emergency medicine, critical care units and other hospital settings. Cumberland’s strategy emphasizes in-licensing and acquiring products that have established safety and efficacy profiles but limited market reach, then leveraging its sales network to expand their commercial footprint.

The company’s flagship products include Acetadote (N-acetylcysteine injection), the only FDA-approved antidote for acetaminophen overdose administered intravenously; Vasostrict (vasopressin injection), used to raise blood pressure in adults with vasodilatory shock; Cerebrex (diclofenac sodium injection), an anti-inflammatory agent for managing acute pain and fever; and Dynastat (parecoxib sodium), a COX-2 inhibitor for postoperative pain relief.